Predictive value of neutrophil/lymphocyte ratio for developing acute renal failure in patients with sepsis using colistin in intensive care units

Abstract

Introduction: Sepsis affects millions of people every year all over the world, and despite increasing knowledge over the years and the use of modern antibiotics and resuscitation treatments, it is the most important cause of morbidity and mortality in intensive care units. Nephrotoxicity is a clinical condition that increases morbidity and mortality in the hospitalized patient population, particularly critically ill patients in intensive care. The neutrophil/lymphocyte ratio (NLR) has emerged as a new biomarker that has begun to be investigated in sepsis and post-surgical acute renal failure (ARF). We determined whether changes in NLR are biomarkers for developing ARF in patients using colistin with a diagnosis of sepsis.

Methods: After obtaining ethics committee permission, the files of patients who were followed up in intensive care with a diagnosis of sepsis and who used colistin in their treatment were retrospectively scanned. In our study, the files of 350 patients followed in intensive care were examined, and it was determined that 70 patients diagnosed with sepsis used colistin. The data of 48 patients included in our study were analyzed.

Results: After colistin use, it was observed that 28 (58%) patients developed ARF, and 20 (41.6%) did not develop ARF. There was no significant difference between the groups in terms of ARF development. In the comparison between the groups, although NLR1 was higher in group 2 than in group 1, and NLR2 was higher in group 1 than in group 2, no significant difference was detected. In the intra-group evaluation, although NLR2 was higher than the baseline value in group 1 and lower in group 2, no statistically significant difference was detected.

Conclusion: The NLR results do not constitute a difference that can be used as a predictive value in showing the development of ARF in patients diagnosed with sepsis and receiving colistin treatment.